MIA Free Clinical Webinar – Melanoma in situ: Diagnosis, Management and Patient Wellbeing
Join the Melanoma Institute Australia (MIA) online for an engaging educational webinar designed for all Skin Cancer GPs, General GPs and Nurses who have an interest in skin cancer.
MIA invites you to join us for an engaging educational webinar designed for all Skin Cancer GPs, General GPs and Nurses who have an interest in skin cancer. Melanoma in situ (MIS) can be challenging to differentiate from benign skin lesions, and early detection is the key to successful treatment.
This webinar features a range of multidisciplinary experts.
Dr Christoph Sinz – Dermatologist, Melanoma Institute Australia
Claire Gore Clinical – Psychology Registrar, Melanoma Institute Australia
Denise Wilson – Dermatology Clinical Nurse Specialist, Melanoma Institute Australia
Shahn Coburn – Host Senior Clinical Nurse Consultant, Melanoma Institute Australia
Melanoma in situ: Diagnosis, management and patient wellbeing:
- How to recognise clinical presentations and diagnose MIS, best practice management and when to refer (Dermatologist Dr Christoph Sinz)
- The dermatology nursing role for topical treatments for lentigo maligna (CNS Denise Wilson)
- Communicating the diagnosis to the patient and identifying when to offer support (Psychologist Claire Gore)
Q&A will be available at the conclusion of the webinar.
After this session, participants will be able to:
- Discuss the controversies of the classification of MIS.
- Identify clinical and dermoscopic features of MIS.
- Discuss the appropriate management of MIS and when to refer to a tertiary centre.
- Describe how to effectively communicate a diagnosis of MIS to a patient.
One CPD hour. A certificate of attendance will be provided.
This is an RACGP-approved CPD activity under the RACGP CPD Program (Activity no. 646242).
For further information, please contact Danielle Fischer, Education Program Manager: firstname.lastname@example.org
Melanoma Institute Australia’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.